GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Horizon Therapeutics PLC (BSP:H1ZN34) » Definitions » Forward PE Ratio

Horizon Therapeutics (BSP:H1ZN34) Forward PE Ratio : 21.10 (As of Apr. 26, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Horizon Therapeutics Forward PE Ratio?

Horizon Therapeutics's Forward PE Ratio for today is 21.10.

Horizon Therapeutics's PE Ratio without NRI for today is 62.19.

Horizon Therapeutics's PE Ratio (TTM) for today is 62.19.


Horizon Therapeutics Forward PE Ratio Historical Data

The historical data trend for Horizon Therapeutics's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Horizon Therapeutics Forward PE Ratio Chart

Horizon Therapeutics Annual Data
Trend 2022-12 2023-04
Forward PE Ratio
22.08 23.04

Horizon Therapeutics Quarterly Data
2022-03 2022-06 2022-09 2022-12 2023-03
Forward PE Ratio 16.37 14.84 12.52 22.08 22.27

Competitive Comparison of Horizon Therapeutics's Forward PE Ratio

For the Drug Manufacturers - General subindustry, Horizon Therapeutics's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Horizon Therapeutics's Forward PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Horizon Therapeutics's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Horizon Therapeutics's Forward PE Ratio falls into.



Horizon Therapeutics Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Horizon Therapeutics  (BSP:H1ZN34) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Horizon Therapeutics Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Horizon Therapeutics's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Horizon Therapeutics (BSP:H1ZN34) Business Description

Traded in Other Exchanges
N/A
Address
70 St. Stephen’s Green, Dublin, IRL, D02 E2X4
Horizon Therapeutics PLC is a biotechnology company. The company is focused on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Some of its pipeline products include UPLIZNA; HZN-825; Dazodalibep; Daxdilimab; TEPEZZA and others.

Horizon Therapeutics (BSP:H1ZN34) Headlines

No Headlines